In January 2019 the World Health Organization issued a collection of formal recommendations to reschedule cannabis and cannabis-related substances. These present an opportunity for African governments and civil society to further decolonise drug control approaches on the continent, as well as to strengthen the international legal basis for emerging medicinal cannabis programmes in several African countries.
This research by the Research Consortium on Drugs and the Law (Colectivo de Estudios Drogas y Derecho, CEDD) analyzes a duality facing Latin America: the prohibitionist discourse and its effects on human rights persist, alongside reforms to laws and policies related to the use of cannabis.
An official policy of giving a low law enforcement priority to small-scale possession or production of cannabis for personal use led to the emergence of Cannabis Social Clubs around Belgium. However, the attitude to cannabis can vary widely at the local level, and the future of these organised user groups is unclear. Produced as part of a the "New Approaches in Harm Reduction Policies and Practices" project, this Country Report seeks to understand the drivers of Belgian cannabis policy today, and the possibilities for its future.
Tom Blickman, Katie Sandwell, Dania Putri, Xabier Arana, Tom Decorte, Vibeke Asmussen Frank, Dirk J. Korf, Ingo Ilja Michels, Maj Nygaard-Christensen, Tim Pfeiffer-Gerschel, Heino Stöver, Bernd Werse, Frank Zobel
20 March 2019
In order to better understand the situation around, and possibilities for, local and regional cannabis regulation, a series of six country reports were developed. The country reports provide detailed information about the state of cannabis policy, and the possibilities for change, within each country. This Report summarises some of the key findings from the research and explores opportunities, obstacles, and strategies for cannabis regulation at the municipal and regional level.
In the 1990s Switzerland was one of the leaders of a movement towards harm reduction for heroin users. Today, the country is also re-thinking its cannabis policy, with municipalities pushing for experiments in more progressive models of regulation, and citizens pushing for legislative reform. Produced as part of a the "New Approaches in Harm Reduction Policies and Practices" project, this Country Report seeks to understand the drivers of Swiss cannabis policy today, and the possibilities for its future.
Countries that embrace legal regulation find themselves in breach of international law. In this video, we explain a strategy to resolve those treaty tensions and to enable progressive and sustainable change at the global level.
Local and regional authorities across Europe are confronted with the negative consequences of a persisting illicit cannabis market. Increasingly, local and regional authorities, non-governmental pressure groups and grassroots movements are advocating a regulation of the recreational cannabis market.
Heino Stöver, Ingo Ilja Michels, Bernd Werse, Tim Pfeiffer-Gerschel
29 March 2019
While medical cannabis is well accepted in Germany and small-scale possession is officially decriminalized, many cities are struggling with high levels of street dealing. A number of cities are pushing for different kinds of public "experiments" in legal distribution that would allow them to better control cannabis in their jurisdictions. Produced as part of a the "New Approaches in Harm Reduction Policies and Practices" project, this Country Report seeks to understand the drivers of German cannabis policy today, and the possibilities for its future.
The Netherlands has long been considered a leader of progressive drug policy, but it is increasingly being left behind by policy innovations outside Europe. Nonetheless Dutch cities are leading the way towards more progressive and locally adapted cannabis policies. Produced as part of a the "New Approaches in Harm Reduction Policies and Practices" project, this Country Report seeks to understand the drivers of Dutch cannabis policy today, and the possibilities for its future.
Martin Jelsma, Neil Boister, David Bewley-Taylor, Malgosia Fitzmaurice, John Walsh
15 March 2018
Legal tensions are growing within the international drug control regime as increasing numbers of member states move towards or seriously consider legal regulation of the cannabis market for non-medical purposes. Amongst reform options not requiring consensus, inter se modification appears to be the most ‘elegant’ approach and one that provides a useful safety valve for collective action to adjust a treaty regime arguably frozen in time.
Three United Nations Conventions provide the international legal framework on drug control, instructing countries to limit drug supply and use to medical and scientific purposes. Yet, debate continues on the decriminalisation, or even legalisation, of drugs, particularly cannabis. Models under development for the legal supply of cannabis are described in this analysis, as well as some of the questions they raise.
Part of the ‘Perspectives on drugs’ (PODs) series, launched alongside the annual European Drug Report, these designed-for-the-web interactive analyses aim to provide deeper insights into a selection of important issues.
After decades of tolerance, cannabis policy in Denmark has seen increasing crackdowns, driven by fears about violence and illegal drug markets. However, some activists and politicians argue that another way is possible. Produced as part of a the "New Approaches in Harm Reduction Policies and Practices" project, this Country Report seeks to understand the drivers of Danish cannabis policy today, and the possibilities for its future.
After decades of relative tolerance towards Cannabis in Spain, the Constitutional Court decides that cannabis clubs are criminal. Years of government criminalizing strategy pay off. The national parliamentary debate can no longer be postponed.
The recent publication of two single pieces of legislation - the amended 1993 Narcotic Drugs and Psychotropic Substances Law and the first National Drug Control Policy - is likely to form the basis of Myanmar’s drug policy for several years to come. What does it mean for the country’s transition towards an evidence-based approach to drug control, and how can the gaps between the two documents be addressed?